Plenary keynote lectures (tentative as of May 8th , 2008)
Category Date Tentative Title Speaker
Antimicrobial resistance March 18
10:40 - 11:20
Antimicrobial resistance : the next pandemic is coming Robert Moellering
(USA)
March 18
11:20 - 12:00
Asia as an epicenter of antimicrobial resistance :
past, present & future
 Jae-Hoon Song
(Korea)
Emerging infectious
problems in Asia-Pacific
region		 March 18
16:10 - 16:50
XDR Gram-negative bacilli : Do we have therapeutic options ? David Paterson
(Australia)
March 18
16:50 - 17:30
Pandemic flu : how well we prepare in Thailand? Supamit Chunsuttiwat
(Thailand)
Antimicrobial treatment in the era of resistance
 March 19
10:40 - 11:20
Treatment of HIV/AIDS after the HAART’s first decade David Cooper
(Australia)
March 19
11:20 - 12:00
Evolution of antimicrobial therapy in the era of resistance :
an endocarditis model
 Walter Wilson
(USA)
Prevention and control of resistance
March 19
16:10 - 16:50
A pharmacodynamic approach to prevent emergence of
resistance		 Johan Mouton
(The Netherlands)
March 19
16:50 - 17:30
New strategies for managing biofilm-associated bacterial infections and antibiotic resistance Robin Patel
(USA)
New antimicrobial agents March 20
10:40 - 11:20
Understanding mechanisms of antimicrobial resistance :
the first clue to develop novel agents
 David Livermore
(UK)
March 20
11:20 - 12:00
Discovery of novel antibacterial agents : where are we ? Karen Bush
(USA)
Day 1 (March 18th ) : Epidemiology, mechanism and detection of resistance
Session Tentative Topic Speaker
Mar. 18 (08:30 - 10:30 )
S1
MRSA, VISA &
VRSA
 Global emergence of CA-MRSA : an update Jae-Hoon Song
(Korea)
Relationship of antimicrobial resistance and virulence in MRSA Robert Moellering
(USA)
VISA,hVISA&VRSA: How do they emerge? Keiichi Hiramatsu
(Japan)
S2
Streptococcus pneumoniae
 Epidemiology and mechanism of pneumococcal resistance ; an update Donald Low
(Canada)
Colonization and resistance : a dynamic approach Ron Dagan
(Israel)
Risk factors for pneumococcal resistance Keith Klugman
(USA)
S3
What's new in the clinical micro lab 		In vitro detection of resistance : what’s new ? Mary Jane Ferraro
(USA)
Update on genotyping methods to detect resistance Franklin Cockerill
(USA)
Laboratory detection of antifungal resistance; facts and controversies David Ellis
(Australia)
Mar. 18 (14:00 - 16:00 )
S4
ESBL &
beta-lactamases
 Global outbreaks of ESBLs :
why CTX-M spread more than TEM & SHV mutants?		 David Livermore
(UK)
Global spread of class A (KPC and metallo) carbapenemases Karen Bush
(USA)
Emerging OXA carbapenemase Kyung-Won Lee
(Korea)
S5
MDR GNB		 Fluoroquinolone resistance among pathogenic Gram-negative bacilli Hui Wang
(China)
Resistance of the Enterobacteriaceae to carbapenems and beta-lactamase inhibitors David Paterson (Australia)
MDR/PDR non-fermenters : an emerging threat in nosocomial infections Po-Ren Hsueh (Taiwan)
S6
HIV		 Global epidemiology of HIV/AIDS : focus on Asian epidemics Adeeba Kamarulzaman
(Malaysia)
Metabolic effects of HIV infection and antiretroviral therapy David Cooper (Australia)
Detection of anti-retroviral resistance in limited resource settings Ruengpung Sutthent (Thailand)
Day 2 (March 19th ) : Treatment of major infectious diseases in the era of resistance
Session Tentative Topic Speaker
Mar. 19 (08:30 - 10:30 )
S7
CAP
(interactive)
 Case : Pneumococcal pneumonia : what should be an optimal therapy ? Donald Low
(Canada)
Case : CAP with respiratory failure on day 2 in an elderly Amorn Leelarasamee
(Thailand)
Case : CAP with respiratory failure in tropical region Yupin Suputtamongkol (Thailand)
S8
Tropical
infections		 Dengue hemorrhagic fever : how to avoid pitfall in therapy Terapong Tantawichien (Thailand)
Rickettsial infections in tropical region Nicholas Day (Thailand)
Melioidosis : updates on epidemiology and treatment Visanu Thamlikitkul (Thailand)
Chikungunya fever : why spread across tropical countries Ban Hock Tan (Singapore)
S9
New guidelines for treatment of invasive mycoses		 Emerging threat of invasive fungal infections Bin Cao
(China)
Guidelines for invasive aspergillus and other mould Thomas Patterson (USA)
Guidelines for candidiasis TBD
Guidelines for cryptococcosis Tania Sorrell (Australia)
Mar. 19 (14:00 - 16:00 )
S10
MRSA/VRSA
infections (interactive)
 Cases of CA-MRSA, VISA/hVISA or VRSA infections Walter Wilson
(USA)
Optimal therapy for CA-MRSA, VISA and VRSA infections Robert Moellering (USA)
S11
Pediatric
infections 		Bacterial meningitis in children Nancy Henry
(USA)
Otitis media in the era of resistance Ron Dagan
(Israel)
Management of HIV infection in children Kulkanya Chokephaibulkit (Thailand)
S12
Antimicrobial resistance in animal and animal products; impact on human health 		Transmission of antimicrobial resistance in animal and human John Turnidge (Australia)
Antimicrobial resistance in animal and animal hospitals Yong-Ho Park
(Korea)
Risk management of antimicrobial resistance in animal and human by risk assessment TBD
Day 3 (March 20th ) : Prevention and control of antimicrobial resistance
Session  Tentative Topic Speaker
Mar. 20 (08:30 - 10:30 )
S13
New issues in
PK/PD
Which clinical breakpoint should we use-EUCAST, CLSI or ? John Turnidge (Australia)
Pharmacodynics and indications of new antimicrobials Johan Mouton
(The Netherlands)
Pharmacodynics of antimalarials Kesara Na-Bangchang (Thailand)
S14
Antibiotic control strategies in Asia
(Panel discussion)
 How important is antibiotic control to prevent resistance ? Victor Lim
(Malaysia)
Policy and strategies in Asian countries (4countries) :
Hong Kong, Singapore, Taiwan, Japan (panel discussion)
 Wing Hong Seto (HongKong),
Paul Tambyah (Singapore),
Po-Ren Hsueh (Taiwan),
Satoshi Hori (Japan)
S15
Vaccines for
prevention and
control of resistance
 Pneumococcal conjugate vaccine: a model for control of resistance ? Keith Klugman
(USA)
Current status on therapeutic TB vaccines Sang-Nae Cho
(Korea)
Malaria vaccine Nicholas White (Thailand)
Mar. 20 (14:00 - 16:00 )
S16
Novel antimicrobial agents		 New topoisomerase inhibitors/fluoroquinolones John Turnidge (Australia)
New protein synthesis inhibitors (oxazolidinones and ketolides) Robin Patel
(USA)
Antimicrobial and host defense peptides : what is the future ? Robert Hancock
(USA)
New antimicrobial agents developed in China Yong Hong Xiao
(China)
S17
Nosocomial infection control		 Effective control of nosocomial infection : What’s new?: Wing Hong Seto
(Hong Kong)
Infection control of endemic MRSA - recent advances and future challenges Somwang Danchaivijitr
(Thailand)
Infection control in the face of epidemics:
lessons from the past and plans for the future		 Paul Tambyah (Singapore)
S18
M. tuberculosis		 Emergence of MDR/XDR TB ; epidemiology and dynamics Chen-Yuan Chiang (IUAT)
Rapid diagnosis of MDR/XDR TB Franklin Cockerill (USA)
Current & future treatment strategies against MDR/XDR TB Wing Wei Yew
(Hong Kong)